Miejsce gwajafenezyny w leczeniu chorób układu oddechowego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2020
Słowa kluczowe:
gwajafenezyna, leki wykrztuśne, kaszel
##plugins.themes.bootstrap3.article.main##
Abstrakt
Gwajafenezyna należy do grupy leków wykrztuśnych. Początek jej stosowania przypada na drugą połowę XX w. Badania kliniczne wskazują na skuteczność gwajafenezyny w zmniejszeniu lepkości oraz sprężystości plwociny, czego efektem jest ułatwienie odkrztuszania zalegającej wydzieliny.
Najczęstsze zastosowanie gwajafenezyny obejmuje leczenie ostrych infekcji górnych dróg oddechowych oraz przewlekłego zapalenia oskrzeli, a także błony śluzowej nosa i zatok przynosowych. Wobec dobrej tolerancji oraz bezpieczeństwa leku większość preparatów gwajafenezyny jest dostępna bez recepty.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Białek-Gosk, K. (2020). Miejsce gwajafenezyny w leczeniu chorób układu oddechowego. Medycyna Faktów , 13(1(46), 82-86. https://doi.org/10.24292/01.MF.0120.9
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Ferkol T., Schraufnagel D.: The global burden of respiratory disease. An. Am. Thor. Soc. 2014; 11: 404-406.
2. US National center for Health statistics national Ambulatory Medical care Survey: 2013 State and National Summary Tables 2013.
3. Balsamo R., Lanata L.: Egan CG Mucoactive drugs. Eur. Respir. Rev. 2010; 19(116): 127-133.
4. United States Department of Health and Human Sevices. Cold, Cough, Allergy, Bronchodilator and Antihistaminie Drug products for Over-the Counter Human Use; Expectorant Drug Products for Over-the Counter Human Use; Final Monograph. 21 CFR 341. 1989 Federal Register 54: 8494-8509.
5. Polskie Towarzystwo Farmaceutyczne: Farmakopea Polska VIII. T. 2. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Warszawa 2008: 1889.
6. Kagan L., Lavy E., Hoffman A.: Effect of mode administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm. Pharmacol. Ther. 2009; 22: 260-265.
7. Vandenheuvel W.J., Sith J.L., Siber R.H.: (2-Methoxyphenoxy)lactic acid, the major urinary metabolite of glyceryl guaiacolate in man. J. Pharm. Sci. 1972; 61: 1997-1998.
8. Kaurt G., von Meyer L., Drasch G.: Investigation of guaifenesin metabolism with gas chromatography-mass spectrometry. Arch. Toxicol. 1980; 45: 149-159.
9. Yuta A., Baraniuk J.N.: Therapeutic approaches to mucus hypersecretion. Curr. Allergy Rep. 2005; 5: 243-251.
10. Seagrave J., Albrecht H., Park Y.S. et al.: Effect of guaifenesin on mucin production, rheology and mucociliary transport in differentiated human airway epithelial cells. Exp. Lung Res. 2011; 37: 606-614.
11. Chadoush S.: Objective sputum changes associated with glyceryl guaiacolate in chronic bronchial diseases. Bull. Phisiopatol. Respir. 1973; 9: 452-456.
12. Thompson M.L., Pavia D., McNicol M.W.: A preliminary study of the effect of guaiphenesin on mucociliary clearance from the human lung. Thorax. 1973; 28: 742-747.
13. Sisson J.H., Yonkers A.J., Waldman R.H.: Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest. 1995; 107: 747-751.
14. Dispingaitis P.V., Gayle Y.E.: Effect of guaifenesin on cough reflex sensitivity. Chest 2003; 124(6): 2178-2181.
15. Bennett W.D., Kala D., Duckworth H. et al.: Effect f a single 1200 mg dose Mucinex® on mucilliary and cough clearance during an acute respiratory tract infection. Respir. Med. 2015; 109: 1476-1483.
16. Parvez L., Vaidya M., Sakhardande A. et al.: Evaluation of antitussive agents in man. Pulm. Pharmacol. 1996; 9: 299-308.
17. Albrecht H., Dicpinigaitis P.V., Guenin P.E.: Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infection. Multidiscip. Respir. Med. 2017; 12: 31.
18. Robinson R.E., Cummings W.B., Deffenbaugh E.R.: Effectiveness of guaifenesin as an expectorant: a cooperative double-blind study. Cur. Ther. Res. 1977; 22: 284-296.
19. Kuhn J.J., Hendley J.O., Adams K.F. et al.: Antitussive effect of guaifenesin in young adults with natural colds. Objective and subjective assessment. Chest 1982; 82: 713-718.
20. https://indeks.mp.pl/leki.
21. Perlík F., Janku I., Kordac V.: The effect of guaiphenesin on absorption and bioavailability of paracetamol from composite analgesic preparations. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988; 26(8): 413-416.
22. Global Initiative for Chronic Obstructive Lung Diesease (GOLD); Global strategy for the Diagnostic, Management and Prevention of COPD 2019.
2. US National center for Health statistics national Ambulatory Medical care Survey: 2013 State and National Summary Tables 2013.
3. Balsamo R., Lanata L.: Egan CG Mucoactive drugs. Eur. Respir. Rev. 2010; 19(116): 127-133.
4. United States Department of Health and Human Sevices. Cold, Cough, Allergy, Bronchodilator and Antihistaminie Drug products for Over-the Counter Human Use; Expectorant Drug Products for Over-the Counter Human Use; Final Monograph. 21 CFR 341. 1989 Federal Register 54: 8494-8509.
5. Polskie Towarzystwo Farmaceutyczne: Farmakopea Polska VIII. T. 2. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Warszawa 2008: 1889.
6. Kagan L., Lavy E., Hoffman A.: Effect of mode administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm. Pharmacol. Ther. 2009; 22: 260-265.
7. Vandenheuvel W.J., Sith J.L., Siber R.H.: (2-Methoxyphenoxy)lactic acid, the major urinary metabolite of glyceryl guaiacolate in man. J. Pharm. Sci. 1972; 61: 1997-1998.
8. Kaurt G., von Meyer L., Drasch G.: Investigation of guaifenesin metabolism with gas chromatography-mass spectrometry. Arch. Toxicol. 1980; 45: 149-159.
9. Yuta A., Baraniuk J.N.: Therapeutic approaches to mucus hypersecretion. Curr. Allergy Rep. 2005; 5: 243-251.
10. Seagrave J., Albrecht H., Park Y.S. et al.: Effect of guaifenesin on mucin production, rheology and mucociliary transport in differentiated human airway epithelial cells. Exp. Lung Res. 2011; 37: 606-614.
11. Chadoush S.: Objective sputum changes associated with glyceryl guaiacolate in chronic bronchial diseases. Bull. Phisiopatol. Respir. 1973; 9: 452-456.
12. Thompson M.L., Pavia D., McNicol M.W.: A preliminary study of the effect of guaiphenesin on mucociliary clearance from the human lung. Thorax. 1973; 28: 742-747.
13. Sisson J.H., Yonkers A.J., Waldman R.H.: Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest. 1995; 107: 747-751.
14. Dispingaitis P.V., Gayle Y.E.: Effect of guaifenesin on cough reflex sensitivity. Chest 2003; 124(6): 2178-2181.
15. Bennett W.D., Kala D., Duckworth H. et al.: Effect f a single 1200 mg dose Mucinex® on mucilliary and cough clearance during an acute respiratory tract infection. Respir. Med. 2015; 109: 1476-1483.
16. Parvez L., Vaidya M., Sakhardande A. et al.: Evaluation of antitussive agents in man. Pulm. Pharmacol. 1996; 9: 299-308.
17. Albrecht H., Dicpinigaitis P.V., Guenin P.E.: Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infection. Multidiscip. Respir. Med. 2017; 12: 31.
18. Robinson R.E., Cummings W.B., Deffenbaugh E.R.: Effectiveness of guaifenesin as an expectorant: a cooperative double-blind study. Cur. Ther. Res. 1977; 22: 284-296.
19. Kuhn J.J., Hendley J.O., Adams K.F. et al.: Antitussive effect of guaifenesin in young adults with natural colds. Objective and subjective assessment. Chest 1982; 82: 713-718.
20. https://indeks.mp.pl/leki.
21. Perlík F., Janku I., Kordac V.: The effect of guaiphenesin on absorption and bioavailability of paracetamol from composite analgesic preparations. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988; 26(8): 413-416.
22. Global Initiative for Chronic Obstructive Lung Diesease (GOLD); Global strategy for the Diagnostic, Management and Prevention of COPD 2019.